secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-039997
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience reports Q3 2023 cash of $13.8M; XACIATO milestone triggered
---------------------------------------------------------------------------

- Cash and equivalents $13.8M at September 30, 2023; evaluating financing options.
- R&D expenses increased to $6.7M in Q3 2023 from $4.5M in Q3 2022, driven by Sildenafil Cream and Ovaprene activities.
- G&A expenses unchanged at $2.7M; focus on efficient operations.
- Received $1.8M first commercial milestone payment from Organon for XACIATO US launch.
- On track to start Ovaprene Phase 3 enrollment in Q4 2023 and end-of-Phase 2 meeting for Sildenafil Cream with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/0001493152-23-039997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315223039997/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer